Who is the best donor for haploidentical stem cell transplantation?

Abstract:

:Recent advances in haploidentical stem cell transplantation have enabled the use of human leukocyte antigen-half matched related donors for allogeneic stem cell transplantation and helped overcome one of the most important limitation in transplantation, which is donor availability, especially for the non-Caucasian population and mixed race individuals, extending allogeneic stem cell transplant for almost all patients in need. As many multiple potential related donors may now be available, it is increasingly clear that not all of these donors can provide equivalent transplant outcomes. Here we review the current available evidence of donor characteristics known to be associated with transplant outcomes for different types of haploidentical transplants using unmanipulated grafts (with post-transplant cyclophosphamide-based graft-vs-host prophylaxis and G-CSF and anti-thymocyte globulin approach) as well as modified grafts (with either selective or complete T-cell depletion). While various platforms use haploidentical donors, graft manipulation and approach to prevent graft-vs-host post-transplant may impact on donor selection and transplant outcomes.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Kongtim P,Ciurea SO

doi

10.1053/j.seminhematol.2018.08.003

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

194-200

issue

3

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(18)30109-4

journal_volume

56

pub_type

杂志文章,评审
  • The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation.

    abstract::The prolonged and severe myelosuppression associated with high-dose chemotherapy and autologous bone marrow transplantation is a major causative factor in patient morbidity and mortality resulting from infection and other causes. The recent molecular cloning, in vitro expression, and formulation of recombinant human c...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Peters WP

    更新日期:1989-04-01 00:00:00

  • Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.

    abstract::Hydroxyurea (HU) is the first widely used treatment to have an impact on the severity of disease in adult patients with sickle cell anemia, but limited data are available for younger patients or those with variant genotypes. We reviewed 324 months of experience with HU in 16 patients from 5.3 to 18.4 years of age trea...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rogers ZR

    更新日期:1997-07-01 00:00:00

  • Cobalamin deficiency in patients infected with the human immunodeficiency virus.

    abstract::Serum vitamin B12 levels are often low in human immunodeficiency virus (HIV)-infected patients. However, only a few patients appear to have actual vitamin B12 deficiency. A low red cell folate level accompanying the low vitamin B12 level makes the presence of vitamin B12 deficiency more likely. Our experience suggests...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Remacha AF,Cadafalch J

    更新日期:1999-01-01 00:00:00

  • Immune dysregulation in immune thrombocytopenia.

    abstract::Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.011

    authors: Yazdanbakhsh K,Zhong H,Bao W

    更新日期:2013-01-01 00:00:00

  • Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

    abstract::The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease. This review focuses on a series of new therapeutics ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2009.02.003

    authors: Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG

    更新日期:2009-04-01 00:00:00

  • Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.

    abstract::The farnesyltransferase inhibitors (FTIs) have been shown in early clinical trials to elicit antitumor actions in a broad range of solid and hematologic malignancies. The mechanism of FTI action involves blockade of farnesyltransferase, an enzyme implicated in multiple cell-signaling pathways involved in proliferation...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.35984

    authors: Cortes JE,Kurzrock R,Kantarjian HM

    更新日期:2002-07-01 00:00:00

  • Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes.

    abstract::High-dose chemoradiotherapy with allogeneic bone marrow or peripheral blood stem cell transplantation (SCT) is a potentially curative treatment for advanced or poor-prognosis hematological malignancies. This procedure was initially considered as a means to deliver supralethal doses of chemotherapy and radiation for th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.30909

    authors: Giralt S,Anagnostopoulos A,Shahjahan M,Champlin R

    更新日期:2002-01-01 00:00:00

  • Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

    abstract::Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling is the treatment of choice in children and young adults with severe aplastic anemia (SAA). However, because only 30% of patients have a suitable donor, more aggressive nontransplant immunosuppressive regimens have been used, with re...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90029-5

    authors: Margolis DA,Casper JT

    更新日期:2000-01-01 00:00:00

  • Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.

    abstract::In early studies, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to reduce the depth and duration of granulocytopenia in the settings of cancer chemotherapy and autologous bone marrow transplantation. In patients with myelodysplastic syndrome or aplastic anemia. GM-CSF has p...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Gutterman J,Vadhan-Raj S,Logothetis C,Anaissle E,Estey E,Talpaz M,Kurzrock R

    更新日期:1990-07-01 00:00:00

  • Development of early treatment strategies for high-risk myeloma precursor disease in the future.

    abstract::Smoldering myeloma (SMM) is a precursor state of multiple myeloma. It is defined by an M-protein concentration ≥3 g/dL and/or ≥10% clonal bone marrow plasma cells, in the absence of end-organ damage. Based on clinical observations, the natural history of SMM varies greatly, from stable, monoclonal gammopathy of undete...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.11.009

    authors: Landgren O,Rajkumar SV

    更新日期:2011-01-01 00:00:00

  • Myelodysplastic syndrome in children and adolescents.

    abstract::Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and subsequent frequent development of acute myeloid leukemia (AML). In children and adolescents, MDS are uncommon disorders, accounting for less than 5% of hematopoietic malignancy, with great heterogeneity in presentation...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2007.10.006

    authors: Niemeyer CM,Baumann I

    更新日期:2008-01-01 00:00:00

  • The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.

    abstract::The B-cell receptor (BCR) is of critical importance for normal B cells and for the majority of B-cell malignancies, especially chronic lymphocytic leukemia (CLL). The two major subsets of CLL are biologically distinct, being derived from B cells at different stages of differentiation and carrying unmutated (U-CLL) or ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2014.05.003

    authors: Stevenson FK,Forconi F,Packham G

    更新日期:2014-07-01 00:00:00

  • The use of topoisomerase I inhibitors in multiple myeloma.

    abstract::The standard treatment of multiple myeloma is systemic chemotherapy. Despite 30 years of drug development in myeloma, there are no new drug regimens significantly superior to melphalan and prednisone. In addition, phase II studies of new drugs in myeloma have been disappointing, with low response rates and no prolonga...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Kraut EH,Ju R,Muller M

    更新日期:1998-07-01 00:00:00

  • Clinical evaluation of iron deficiency.

    abstract::While the prevalence of iron deficiency has remained relatively constant, there has been continuing refinement in its laboratory recognition, especially with the recent introduction of serum ferritin and FEP measurements. It is helpful to classify iron deficiency into three stages. Storage iron depletion is identified...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Cook JD

    更新日期:1982-01-01 00:00:00

  • Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease characterized by multiple genetic and epigenetic alterations. The major causes of treatment failure remain disease relapse and treatment toxicity. However, major advances in biological determinants of disease relapse, development of targeted molecules, improvemen...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2015.03.001

    authors: Brissot E,Mohty M

    更新日期:2015-07-01 00:00:00

  • Management of chronic myeloid leukemia: targets for molecular therapy.

    abstract::Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by malignant expansion of bone marrow stem cells. Currently, the only unequivocally curative treatment for CML is allogeneic stem cell transplant. Unfortunately, a large proportion of CML patients are ineligible for such treatment and alternative...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50002

    authors: Barnes DJ,Melo JV

    更新日期:2003-01-01 00:00:00

  • Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

    abstract::Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma. We summarized our experience with thalidomide alone, and then in combination with dexamethasone, for groups of patients with myeloma resistant or relapsing despite standard treatments. Criteria of r...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2003.09.006

    authors: Alexanian R,Weber D,Anagnostopoulos A,Delasalle K,Wang M,Rankin K

    更新日期:2003-10-01 00:00:00

  • Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma.

    abstract::Psoralens plus ultraviolet A (UVA) light inactivate viruses and bacteria as well as leukocytes. A system employing the synthetic psoralen compound amotosalen hydrochloride (S-59), in combination with UVA light, is being developed to decontaminate platelet concentrates and plasma in a blood-bank setting. S-59 is a hete...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90118-0

    authors: Wollowitz S

    更新日期:2001-10-01 00:00:00

  • Screening for hemochromatosis: phenotype versus genotype.

    abstract::Hereditary hemochromatosis is one of the most common inherited disorders among Caucasians of European ancestry. Malregulation of iron absorption from the duodenum eventually leads to iron overload. Although the time required to become iron loaded is variable, it is clear that most homozygotes will eventually become sy...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Edwards CQ,Griffen LM,Ajioka RS,Kushner JP

    更新日期:1998-01-01 00:00:00

  • Myelodysplastic syndromes.

    abstract::These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to ident...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Koeffler HP

    更新日期:1996-04-01 00:00:00

  • Granulocyte transfusions: Current science and perspectives.

    abstract::Severe neutropenia renders patients susceptible to life-threatening bacterial and fungal infections. Despite improvements in supportive care and antimicrobial therapy, morbidity and mortality remains significant. Since the 1960s, granulocyte transfusions have been used to either treat or prevent serious infections in ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2019.11.002

    authors: West KA,Conry-Cantilena C

    更新日期:2019-10-01 00:00:00

  • CD4+CD25+ regulatory T cells and graft-versus-host disease.

    abstract::Peripheral suppression of autoreactive T cells by specialized T-cell populations is one of several mechanisms ensuring self-tolerance within the adaptive immune system. Thymus-derived CD4+CD25+ T cells expressing the transcriptional repressor FOXP3 mediate such immunoregulatory functions and are pivotal for the preven...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.09.006

    authors: Hoffmann P,Edinger M

    更新日期:2006-01-01 00:00:00

  • Management of cancer-related anemia: epoetin alfa and quality of life.

    abstract::Anemia is frequent and significantly adds to the morbidity of cancer patients, and has been associated with decreased quality of life (QOL). Three open-label community-based studies of epoetin alfa in cancer-related anemia (two using three-times-weekly dosing and one using once-weekly dosing) in more than 7,000 patien...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90062-3

    authors: Soignet S

    更新日期:2000-10-01 00:00:00

  • Risks and benefits of erythropoiesis-stimulating agents in cancer management.

    abstract::Anemia is frequently diagnosed in patients with cancer and its treatment is an important clinical problem. The deficiency in red blood cells (RBCs) can be a debilitating problem, and anemia correlates with poor performance status, deteriorates quality of life, and may negatively influence the prognosis of cancer patie...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.04.004

    authors: Beutel G,Ganser A

    更新日期:2007-07-01 00:00:00

  • The virome in hematology-Stem cell transplantation and beyond.

    abstract::The virome has been recently studied in hematology and mostly in the setting of allogeneic hematopoietic stem cell transplantation. However, in hematology (as in the setting of nonhematological disorders) the study of the microbiome (that indeed includes the virome) is a growing field. The overall field is moving beyo...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2020.05.001

    authors: Legoff J,Michonneau D,Socie G

    更新日期:2020-01-01 00:00:00

  • Interactions of platelets and endothelial cells with erythrocytes and leukocytes in thrombotic thrombocytopenic purpura.

    abstract::In both normal and abnormal vascular biology, platelet-leukocyte-RBC-EC adhesive and functional interactions appear to play a significant role. The clinical hallmarks of the TTP/HUS syndromes, including prominent platelet aggregation and thrombi without prominent soluble coagulation system activation along with microa...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith BR,Rinder HM

    更新日期:1997-04-01 00:00:00

  • Transplant strategies for idiopathic myelofibrosis.

    abstract::Idiopathic myelofibrosis (IMF) is a clonal stem cell disorder and is one of the four major myeloproliferative disorders, which include essential thrombocythemia (ET), polycythemia vera (PV), and chronic myelogenous leukemia (CML). Patients may be asymptomatic at the early stages, but later progress to marrow fibrosis,...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.02.009

    authors: McCarty JM

    更新日期:2004-04-01 00:00:00

  • The new direct oral anticoagulants in special indications: rationale and preliminary data in cancer, mechanical heart valves, anti-phospholipid syndrome, and heparin-induced thrombocytopenia and beyond.

    abstract::The present review will briefly summarize the interplay between coagulation and inflammation, highlighting possible effects of direct inhibition of factor Xa and thrombin beyond anticoagulation. Additionally, the rationale for the use of the new direct oral anticoagulants (DOACs) for indications such as cancer-associa...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2014.03.002

    authors: Alberio L

    更新日期:2014-04-01 00:00:00

  • Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.

    abstract::The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Tefferi A

    更新日期:1999-01-01 00:00:00

  • Treatment approach to newly diagnosed diffuse large B-cell lymphoma.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma in western countries. High prognostic heterogeneity is observed among patients with DLBCL with long-term survival ranging from 30% to more than 90% according to clinic-biological prognostics such as the International Prognostic ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2015.01.001

    authors: Bachy E,Salles G

    更新日期:2015-04-01 00:00:00